Implications of therapy choice on overall survival in metastatic renal cell carcinoma: A single institution experience

Simrit Parmar, Alfred W. Rademaker, Bing B. Fung, James M. Kozlowski, Timothy M. Kuzel*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Purpose: To compare the effect of high-dose interleukin-2 (HD IL-2) vs other cytokine therapies on 1-, 2, and 5-yr overall survival in patients with metastatic renal cell cancer (RCC). Patients and methods: We conducted a retrospective chart review of patients with untreated metastatic RCC treated by a single investigator. The different treatment groups included HD IL-2, low-dose IL-2 alone or in combination, interferon α alone and other therapies. The primary end point was survival from time of treatment. Results: A total of 85 patients were studies with a median follow up of 13 mo (0.6-112.9). Median age at treatment was 59 yr with predominantly male patients and histology of clear cell type. Thirty-four percent received HD IL-2 and treatment was initiated less than 6 mo from the time of diagnosis in 66%. For all patients, median survival was 16 mo with a 5-yr survival of 12%. Two factors were good predictors of overall survival: Karnofsky performance status (KPS) of 100 (p < 0.0001) and soft tissue metastasis (p = 0.01). When comparing HD IL-2 to all other groups, median survival was 18 vs 14 mo and 1-yr survival was 74% vs 51%, respectively. Conclusion: HD IL-2 is associated with clinically meaningful improvement in median and 1-yr survival.

Original languageEnglish (US)
Pages (from-to)399-405
Number of pages7
JournalMedical Oncology
Issue number4
StatePublished - Dec 1 2005


  • Interferon-alpha
  • Interkeukin-2
  • Metastatic renal cell cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Implications of therapy choice on overall survival in metastatic renal cell carcinoma: A single institution experience'. Together they form a unique fingerprint.

Cite this